Clinical trial
An Adaptive Phase 2 Study of Tipifarnib in Subjects With Myelodysplastic Syndromes
NCT02779777 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Adaptive Phase 2 Study of Tipifarnib in Subjects With Myelodysplastic Syndromes
- Lead sponsor
- Kura Oncology, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 1, 2016
- Completion date
- August 28, 2018
- Enrollment
- 16 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.